{"id":335888,"date":"2019-07-31T00:00:00","date_gmt":"2019-07-30T22:00:00","guid":{"rendered":"https:\/\/medizinonline.com\/early-use-of-cdk4-6-inhibitors-investigated\/"},"modified":"2019-07-31T00:00:00","modified_gmt":"2019-07-30T22:00:00","slug":"early-use-of-cdk4-6-inhibitors-investigated","status":"publish","type":"post","link":"https:\/\/medizinonline.com\/en\/early-use-of-cdk4-6-inhibitors-investigated\/","title":{"rendered":"Early use of CDK4\/6 inhibitors investigated"},"content":{"rendered":"<p><strong>Targeted therapies are currently used primarily in locally advanced or metastatic breast cancer. Recent study data now suggest that earlier-stage sufferers may also benefit.<\/strong><\/p>\n<p> <!--more--> <\/p>\n<p>CDK4\/6 inhibitors have already demonstrated efficacy in advanced or metastatic breast cancer. They are associated with a significant prolongation of progression-free survival in combination with anti-hormonal therapy. They have now become the standard of care in endocrine-sensitive metastatic carcinoma. Due to the positive response and good tolerability, the compounds have now been investigated in endocrine sensitive tumors in the early disease phase.<\/p>\n<p>The derailed cell growth is due, among other things, to a dysregulation in the cell cycle, which is controlled by cyclins and cyclin-dependent kinases (CDKs). Interaction with cyclin D activates CDK4\/6, which have been shown to be regulators of the cell cycle. By phosphorylating the retinoblastoma tumor suppressor protein, they trigger the transition from G1 phase to the proliferative S phase of the cell cycle. Accordingly, inhibition of cyclin-dependent kinases can curb cell division.<\/p>\n<h2 id=\"neo-adjuvant-use\">Neo-adjuvant use<\/h2>\n<p>After diagnosis, CDK4\/6 inhibitors were given for two and four weeks, respectively, and KI-67 was measured as evidence of response. It was shown that s the drugs could significantly slow down proliferation in some cases even without additional endocrine therapy. The goal would be to significantly reduce the risk of metastasis.<\/p>\n<p><em>Source: Congress St. Gallen International Breast Cancer Conference 2019<\/em><\/p>\n<p>&nbsp;<\/p>\n<p><em>InFo ONCOLOGY &amp; HEMATOLOGY 2019; 7(2-3): 38 (published 6\/21\/19, ahead of print).<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Targeted therapies are currently used primarily in locally advanced or metastatic breast cancer. Recent study data now suggest that earlier-stage sufferers may also benefit.<\/p>\n","protected":false},"author":7,"featured_media":90296,"comment_status":"closed","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"pmpro_default_level":"","cat_1_feature_home_top":false,"cat_2_editor_pick":false,"csco_eyebrow_text":"Breast Cancer","footnotes":""},"category":[11513,11400,11370,11548],"tags":[13554,13561,28237,11767],"powerkit_post_featured":[],"class_list":["post-335888","post","type-post","status-publish","format-standard","has-post-thumbnail","category-congress-reports","category-gynecology","category-oncology","category-rx-en","tag-breast-cancer-en","tag-breast-cancer-en-2","tag-neo-adjuvant-therapy","tag-targeted-therapy","pmpro-has-access"],"acf":[],"publishpress_future_action":{"enabled":false,"date":"2026-06-19 04:20:26","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category","extraData":[]},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"wpml_current_locale":"en_US","wpml_translations":{"fr_FR":{"locale":"fr_FR","id":335897,"slug":"utilisation-precoce-des-inhibiteurs-cdk4-6-etudiee","post_title":"Utilisation pr\u00e9coce des inhibiteurs CDK4\/6 \u00e9tudi\u00e9e","href":"https:\/\/medizinonline.com\/fr\/utilisation-precoce-des-inhibiteurs-cdk4-6-etudiee\/"},"it_IT":{"locale":"it_IT","id":335907,"slug":"indagato-luso-precoce-degli-inibitori-di-cdk4-6","post_title":"Indagato l'uso precoce degli inibitori di CDK4\/6","href":"https:\/\/medizinonline.com\/it\/indagato-luso-precoce-degli-inibitori-di-cdk4-6\/"},"pt_PT":{"locale":"pt_PT","id":335914,"slug":"utilizacao-precoce-dos-inibidores-cdk4-6-investigados","post_title":"Utiliza\u00e7\u00e3o precoce dos inibidores CDK4\/6 investigados","href":"https:\/\/medizinonline.com\/pt-pt\/utilizacao-precoce-dos-inibidores-cdk4-6-investigados\/"},"es_ES":{"locale":"es_ES","id":335877,"slug":"se-investiga-el-uso-precoz-de-los-inhibidores-cdk4-6","post_title":"Se investiga el uso precoz de los inhibidores CDK4\/6","href":"https:\/\/medizinonline.com\/es\/se-investiga-el-uso-precoz-de-los-inhibidores-cdk4-6\/"}},"_links":{"self":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/posts\/335888","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/comments?post=335888"}],"version-history":[{"count":0,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/posts\/335888\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/media\/90296"}],"wp:attachment":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/media?parent=335888"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/category?post=335888"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/tags?post=335888"},{"taxonomy":"powerkit_post_featured","embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/powerkit_post_featured?post=335888"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}